Top Abstract Purchase Related
Home
>
Node
>
Subnode

Interferon system in viral hepatitis

Lisker Melman, M.

Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 42 Suppl: 92-96

1990

ISSN/ISBN: 0034-8376
PMID: 19256144
Document Number: 360695
Interferons are host-derived proteins produced by cells in response to viral and other stimuli. Three major types of interferons have been described: alpha, beta and gamma, which can be distinguished structurally, biochemically and antigenically. Interferon limits virus spread from focal sites of infection, shortens the period of viremia and decreases the severity of acute systemic infection. The problems of shortage, expense and lack of purity of natural interferons were overcome and now interferons are available for clinical trials. Interferons have shown to be a very promising group of agents against chronic viral hepatitis.

Document emailed within 1 workday
Secure & encrypted payments

Stancek, D.; Fuchsberger, N.; Oltman, M.; Schmeisser, H.; Kontsek, P.; Jahnová, E.; Hajnická, V. 2001: Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2 Acta Virologica 45(5-6): 287-292
Pirovino, M. 1992: Interferon treatment of chronic viral hepatitis Therapeutische Umschau. Revue Therapeutique 49(5): 302-309
Desai, H.G.; Gupte, P.A. 2005: Should acute viral C hepatitis be treated with interferon? Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology 24(2): 66-67
Wright, H.I. 1990: Interferon treatment of chronic viral hepatitis G.E.N 44(1): 71-77
Beker, S.; Pujol, F.H.; Beker, B. 1995: Is the treatment of chronic viral hepatitis C with interferon-alpha effective? G.E.N 49(2): 165-169
Alscher, D.M.; Bode, J.C. 1992: Therapy of acute and chronic viral hepatitis C (non-A, non-B) with interferon-alpha Medizinische Klinik 87(10): 532-539
Soriano, V.; García-Samaniego, J. 1994: Therapy with interferon in HIV-infected patients with chronic viral hepatitis Revista Clinica Espanola 194(10): 887-889
Andreĭchin, M.A.; Rudchik, A.S.; Borak, V.F. 1988: Use of interferon inducers and reaferon in the combined therapy of acute viral hepatitis B Terapevticheskii Arkhiv 60(11): 29-32
Kvitashvili, M.A.; Kuznetsov, V.P.; Pokrovskiĭ, V.I. 1982: Treatment of severe forms of viral hepatitis with injections of human leukocytic interferon Terapevticheskii Arkhiv 54(9): 28-32
Ettinger, O.A.; Nikitin, I.G.; Storozhakov, G.I. 1999: Autoimmune lesions of thyroid as complications of interferon treatment of chronic viral hepatitis Terapevticheskii Arkhiv 71(12): 69-72
Juszczyk, J.; Baka-Cwierz, B.; Beniowski, M.; Berak, H.; Bolewska, B.; Boroń-Kaczmarska, A.; Cianciara, J.; Cieśla, A.; Dziambor, A.; Gasiorowski, J.; Gietka, A.; Gliwińska, E.; Gładysz, A.; Gonciarz, Z.; Halota, W.; Horban, A.; Inglot, Młgorzata.; Janas-Skulina, U.; Janczewska-Kazek, E.; Jaskowska, J.; Jurczyk, K.; Knysz, B.; Kryczka, Wław.; Kuydowicz, J.; Lakomy, E.A.; Logiewa-Bazger, B.; Lyczak, A.; Mach, T.; Mazur, Włodzimierz.; Michalska, Z.; Modrzewska, R.; Nazzal, K.; Pabjan, Pł.; Piekarska, A.; Piszko, Pł.; Sikorska, K.; Szamotulska, K.; Sliwińska, M 2005: Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report) Przeglad Epidemiologiczny 59(3): 651-660
Xin-Hua, W.; Chang-Qing, L.; Xing-Bo, G.; Lin-Chun, F. 2001: A comparative study of Phyllanthus amarus compound and interferon in the treatment of chronic viral hepatitis B Southeast Asian Journal of Tropical Medicine and Public Health 32(1): 140-142
Kokoreva, L.N.; Zmyzgova, A.V.; Shalygina, N.B. 1996: The interferon therapy of patients with chronic viral hepatitis: the factors affecting the treatment results Terapevticheskii Arkhiv 68(2): 10-14
Nakamura, H.; Ogawa, H.; Kuroda, T.; Yamamoto, M.; Enomoto, H.; Kishima, Y.; Yoshida, K.; Ito, H.; Matsuda, M.; Noguchi, S. 2002: Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus Hepato-Gastroenterology 49(47): 1373-1376
Pokrovskiĭ, V.I.; Zmyzgova, A.V.; Botsvadze, E.S.; Andreĭchin, M.A.; Frolov, V.M.; Murzabaeva, R.T.; Mesniankin, A.P.; Kokareva, L.N.; Malinovskaia, V.V. 1990: An assessment of the therapeutic efficacy of gene-engineered human alpha 2-interferon in patients with acute viral hepatitis B Terapevticheskii Arkhiv 62(2): 139-143
Pastore, G.; Santantonio, T.; Monno, L.; Milella, M.; Luchena, N.; Angarano, G. 1988: Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B Hepato-Gastroenterology 35(2): 57-61
Hrycewycz, N.; Sandres, K.; Barange, K.; Pascal, J.P.; Izopet, J.; Payen, J.L. 2001: Eradication of hepatitis C virus after 3 months of interferon and ribavirin treatment in an a interferon non-responder patient with chronic hepatitis C Gastroenterologie Clinique et Biologique 25(11): 1041-1042
Mozer-Lisewska, I.; Dworacki, G.; Kaczmarek, E.; Słuzewski, W.; Kowala-Piaskowska, A.; Figlerowicz, M.; Kaczmarek, M.; Zeromski, J. 2005: Alterations within white blood cell subsets in children with chronic viral hepatitis C before treatment with pegylated interferon and ribavirin Przeglad Epidemiologiczny 59(2): 483-489
Zielińska, W.; Korczak-Rogoń, A.; Paszkiewicz, J.; Kowalik, M.; Cummins, J.M.; Georgiades, J.A. 1996: Comparison of the long-term effects of treatment with oral and parenteral interferon alpha in chronic viral hepatitis patients Archivum Immunologiae et Therapiae Experimentalis 44(5-6): 359-366
Su, S-Yung. 2019: The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan Hepatology International 13(2): 157-164